Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Expected to Post Earnings of -$0.91 Per Share

Equities analysts expect Atara Biotherapeutics, Inc. (NASDAQ:ATRAGet Rating) to announce earnings of ($0.91) per share for the current quarter, Zacks reports. Three analysts have made estimates for Atara Biotherapeutics’ earnings, with the highest EPS estimate coming in at ($0.79) and the lowest estimate coming in at ($0.97). Atara Biotherapeutics also reported earnings per share of ($0.91) in the same quarter last year. The business is expected to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Atara Biotherapeutics will report full-year earnings of ($3.45) per share for the current year, with EPS estimates ranging from ($3.78) to ($2.96). For the next year, analysts anticipate that the firm will post earnings of ($3.08) per share, with EPS estimates ranging from ($4.08) to ($2.51). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRAGet Rating) last issued its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.11. Atara Biotherapeutics had a negative net margin of 1,451.79% and a negative return on equity of 113.94%. During the same period last year, the company posted ($0.86) earnings per share.

ATRA has been the topic of a number of research reports. Citigroup downgraded shares of Atara Biotherapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $15.00 to $8.00 in a report on Monday, May 9th. JPMorgan Chase & Co. cut their price target on shares of Atara Biotherapeutics from $27.00 to $22.00 and set an “overweight” rating on the stock in a report on Monday, March 28th. StockNews.com lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday. Canaccord Genuity Group cut their price target on shares of Atara Biotherapeutics from $78.00 to $67.00 in a report on Tuesday, March 1st. Finally, HC Wainwright restated a “buy” rating and set a $31.00 price target on shares of Atara Biotherapeutics in a report on Thursday, January 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Atara Biotherapeutics currently has a consensus rating of “Hold” and a consensus target price of $30.43.

NASDAQ ATRA opened at $5.13 on Thursday. The company’s 50 day simple moving average is $7.92 and its 200 day simple moving average is $12.85. Atara Biotherapeutics has a 12 month low of $4.84 and a 12 month high of $20.04. The company has a market capitalization of $479.17 million, a P/E ratio of -1.41 and a beta of 1.92.

Several hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its stake in shares of Atara Biotherapeutics by 10.4% in the 1st quarter. JPMorgan Chase & Co. now owns 8,189,899 shares of the biotechnology company’s stock valued at $76,085,000 after buying an additional 772,777 shares in the last quarter. Maverick Capital Ltd. increased its position in shares of Atara Biotherapeutics by 2.0% during the 3rd quarter. Maverick Capital Ltd. now owns 7,855,824 shares of the biotechnology company’s stock worth $140,619,000 after purchasing an additional 151,148 shares in the last quarter. BlackRock Inc. increased its position in shares of Atara Biotherapeutics by 2.2% during the 4th quarter. BlackRock Inc. now owns 7,816,552 shares of the biotechnology company’s stock worth $123,190,000 after purchasing an additional 164,961 shares in the last quarter. State Street Corp increased its position in shares of Atara Biotherapeutics by 45.1% during the 1st quarter. State Street Corp now owns 6,273,617 shares of the biotechnology company’s stock worth $58,282,000 after purchasing an additional 1,949,418 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its position in shares of Atara Biotherapeutics by 99.0% during the 4th quarter. Point72 Asset Management L.P. now owns 4,613,700 shares of the biotechnology company’s stock worth $72,712,000 after purchasing an additional 2,295,400 shares in the last quarter.

About Atara Biotherapeutics (Get Rating)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Stories

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.